Answers are grounded in this paper and cite their sources.
Regulatory factor X 7 ( RFX7 ) nonsense mutations have been found in different human B cell malignancies. We therefore set out to study the role of RFX7 in B cell activation and lymphomagenesis. Here we show that RFX7 truncations cause loss-of-function and dominant-negative effects. Moreover, low RFX7 mRNA levels correlate with worse diffuse large B cell lymphoma prognosis. Accordingly, Rfx7 deletion in B cells accelerates pathogenesis in mouse Bcl6- and p53-loss-driven B cell lymphoma models. Rfx7-deficient B cells exhibit increased Myc activity and enhanced germinal center B cell and plasmablast responses. These alterations are reverted by Myc haploinsufficiency, which provides partial protection from nonsymptomatic p53 −/− Rfx7 −/− B cell lymphoma, but does not prevent detrimental Myc deregulation in aggressive disease. Deletion of Aicda , which favors genomic alterations in activated B cells, limits lymphoma development in the p53 −/− Rfx7 −/− double-hit mouse model. These results indicate that Rfx7 represses B cell activation, Myc activity, and Myc- and activation-induced cytidine deaminase (AID)-dependent pro-lymphomagenic processes.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: